TP53 and neoplasm: We were unable to identify driver mutations from the tumor in the nonmalignant tissue and the sensitivity of ddPCR was unable to resolve a significant shift in the allelic ratio (from 50:50) in the TP53-associated heterozygous SNPs (Fig. S8).